Potential Alternative to Bone Marrow Transplants Awarded FDA Breakthrough Therapy Status


gamida-300x205Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for the Company’s lead product candidate, NiCord®, in development as a novel graft modality for bone marrow transplantation in patients with high risk haematological malignancies (blood cancers) such as leukaemia and lymphoma.

NiCord® is cryopreserved (frozen) umbilical cord blood stem and progenitor cells, that were expanded (population increased) ex-vivo (outside of the body). NiCord® is derived from a single umbilical cord blood unit which has been expanded in culture and enriched with stem and progenitor cells using Gamida Cell’s proprietary NAM technology, and is in development as an investigational therapeutic treatment for blood cancers such as leukemia and lymphoma and for non-malignant haematological diseases.

NiCord® was originally transplanted as a “fresh” product that had to be infused into the patient within a limited number of hours from the moment the product was released from the manufacturing site. This timetable restricted the window for transplantation for the patient and limited the location of manufacturing sites to the vicinity of participating medical centers;it also increased the cost of shipping and logistical support required from manufacturing through delivery.

The first person was successfully transplanted with cryopreserved (frozen) NiCord in the company’s ongoing Phase I/II clinical study for blood cancer patients in January 2015.

The designation “breakthrough therapy” is granted to drugs that are intended to treat a serious or life-threatening condition, and where preliminary clinical evidence suggests substantial improvement over existing therapies. It is meant to expedite the development and review of new therapies by giving the company extensive FDA guidance for more efficient and accelerated drug development programs.

We are very pleased the FDA has recognized the potential of NiCord to address the unmet clinical need in bone marrow transplantation,” Dr. Yael Margolin, president and CEO of Gamida Cell, said in a press release.

The breakthrough therapy designation creates the foundation for a joint and concerted effort between the FDA and Gamida Cell to bring this important therapy faster to patients. We look forward to continuing our close cooperation with the FDA and other regulatory agencies to a positive conclusion as we prepare for commercialization,” Margolin said.

Each year, more than 60,000 patients with high-risk blood cancers should receive bone marrow transplants, which are currently the only potential cure for these patients.

cancer cell made in 3d softwareBut to qualify for the treatment, patients require a donor with fully matched tissue typing, which is often difficult to find. As a result, only about half of patients who are supposed to get bone marrow transplants actually receive one.

With NiCord, Gamida Cell is trying to make a difference for patients who can’t find matching donors. NiCord is an alternative to bone marrow transplants that instead uses cells collected from the blood of the umbilical cord. These cells are then cultured using a proprietary NAM platform technology, which enriches the cultured cells in highly functional stem and progenitor cells, as well as dendritic cells.

Gamida Cell believes that NiCord can provide a transplant option that is available to all patients in need, based on results from the pilot and Phase 1/2 studies of NiCord. Compared to unmanipulated umbilical cord blood, the therapy has improved time to neutrophil engraftment (incorporating the transplanted cells into the recipient tissue) from 21 days to 10 days; the number of patients achieving neutrophil engraftment (75% versus 18%); faster platelet engraftment (32 days vs. 46 days); and lower transplant-related mortality (19% vs. 39%).

Additionally, NiCord induced fewer infections and reduced the length of time spent in the hospital.

Gamida Cell is now waiting for positive feedback from the FDA and the European Medicines Agency (EMA) regarding the outline of the Phase 3 trial, after which it will soon begin assessing NiCord in patients with blood cancers.

Gamida Cell presented additional positive data of Nicord® in blood cancer patients at EBMT 2016 in an oral session titled Transplantation of Ex vivo Expanded Umbilical Cord Blood (NiCord®) Results in Decreased Infection Burden and Hospital Length of Stay in the First 100 Days by Sarah Anand, MD and Mitchell Horwitz, MD, both from the Duke University School of Medicine and the Duke Cancer Institute, at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain in April.

Dr. Horwitz said, “We saw a significant reduction in serious bacterial infections during the first 100 days in the NiCord group. This is encouraging because this type of infection is a major cause of early death following UCB transplantation. We also saw a significant reduction in hospitalization time in the NiCord group, indicating a faster recovery of these patients in comparison to those transplanted with standard umbilical cord blood. These results demonstrate that the rapid hematopoietic recovery from NiCord transplantation results in clinical benefit, in comparison to similar site controls.”

 

Advertisements

About LFCT

This is a blog about CHILDHOOD CANCER and CHILDHOOD CANCER AWARENESS Little Fighters Cancer Trust is a non-profit organisation that offers support and aid to Children with Cancer and their families. When a child is diagnosed with cancer it affects the whole family. One of the parents, usually the mother, must give up their job to care for the child and this creates financial problems for the family. In South Africa especially the majority of these families are not well-to-do; many of them are rural. A diagnosis of cancer can wipe out any family’s finances, let alone a poor family. The costs of special medications, special diets, hospital stays, transport to and from the hospital or clinic and accommodation and food costs for the mother who spends most of the time at her child’s bedside are astronomical. These are the people and problems that fall through the cracks, and these are the people that Little Fighters Cancer Trust has pledged to help in any way possible. LFCT takes a holistic approach to assisting the Children with Cancer and their Families, with the main aim to be the preservation of individual dignity and pride. Little Fighters Cancer Trust also focuses on promotion and advocacy of National Childhood Cancer Awareness in an effort to increase awareness of Early Warning Signs of Childhood Cancer. This would result in earlier diagnosis, giving the Child with Cancer more of a chance at Treatment and Survival. See "About" for more Background info

Posted on 16 November, 2016, in Blog, Cancer Treatments, Medical Treatments, Research and tagged , , , , , , , . Bookmark the permalink. Leave a comment.

Please help us to Raise Childhood Cancer Awareness by Commenting and Sharing

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: